Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

April 10, 2026 Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision — a program that recently delivered landmark wins in two pivotal COPD trials Her appointment […]

PEGS Europe 2025

November 12, 2025 Presentation by Mary Ann Pohl, Ph.D., Director of Alliance Management, Ailux

Ailux Announces Posters at American College of Rheumatology (ACR) Convergence 2025

October 27, 2025 SHANGHAI (CHINA) and SOMERVILLE, MA (US) — October 27, 2025 — Ailux, an innovator in AI-powered biologics and a subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced scientific presentations at the ACR Convergence 2025. Ailux leveraged an AI-powered antibody discovery platform to precisely design two therapeutic candidates […]

Ailux Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

October 10, 2024 CAMBRIDGE, MA – October 10, 2024 – XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen), a Johnson & Johnson company, on one of its proprietary biologics AI platforms.Under the agreement, Ailux Biologics grants Janssen and […]